Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 14/20 | 0.60 |
| ▸ | EGFR | P00533 | 4/20 | 0.54 |
| ▸ | FLT1 | P17948 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30611478 | 0.78 | EGFR (0.69) | MKNK1EGFRFLT1RETCDC7 | |
| SCHEMBL13434860 | 0.78 | EGFR (0.69) | MKNK1EGFRFLT1RETCDC7 | |
| SCHEMBL16014470 | 0.75 | MKNK1 (1.00) | MKNK1EGFRFLT1RETCDC7 | |
| SCHEMBL16964046 | 0.74 | MKNK1 (0.64) | MKNK1EGFRFLT1RETCDC7 | |
| SCHEMBL15923731 | 0.74 | MKNK1 (1.00) | MKNK1EGFRFLT1RETCDC7 | |
| SCHEMBL29116330 | 0.73 | MAPT (0.51) | EGFRFLT1ERBB2 | |
| SCHEMBL16963982 | 0.73 | MKNK1 (0.73) | MKNK1EGFRFLT1RETCDC7 | |
| SCHEMBL30611453 | 0.73 | MKNK1 (0.69) | MKNK1EGFRFLT1RET | |
| SCHEMBL4737834 | 0.72 | FADS1 (0.60) | MKNK1EGFRERBB2 | |
| SCHEMBL29116561 | 0.72 | EGFR (0.60) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633201-B2 | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-8633201-B2 | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-20100056548-A1 | THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-03-04 | — | — | US | disclosed |
| US-20100056548-A1 | THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-03-04 | — | — | US | disclosed |
| WO-2007115822-A1 | THIENOPYRIMIDINES HAVING MNKL /MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056548-A1 | THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | CMPK1, DTYMK, NEK9 | MKNK1 29/4885EGFR 4110/4885FLT1 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.